Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Afamelanotide with light therapy for nonsegmental vitiligo
Official title: A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo
Status: Closed to new participants
Description:
Clinuvel, Inc. plans to enroll about 200 participants. Afamelanotide activates a pathway that stimulates melanocytes to make more pigment. Used with UVB light, it may speed or increase repigmentation. Afamelanotide is sold as Scenesse and is approved for erythropoietic protoporphyria; vitiligo would be a new use. Possible effects include nausea, headache, skin darkening, and changes in moles. People age 12 and older may qualify. The study is underway but is no longer accepting new participants.
Start date: October 11, 2023
Completion date: June 01, 2026
Organizer: Clinuvel, Inc.
Contact: See contacts and locations in the ClinicalTrials.gov record
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Any link between vitiligo and military service?
While there isn't specific research directly linking military service to the onset of vitiligo, it's critical to comprehend that vitiligo is a multifaceted disorder influenced b...
- What's the status with official recognition of World Vitiligo Day?
In 2016, the United Nations marked World Vitiligo Day in its International Calendar of Disability Events. However, it was removed in 2019 when the calendar was streamlined to 'M...
- PTSD in Vitiligo?
Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.